Concise Review: Induced Pluripotent Stem Cell-Based Drug Discovery for Mitochondrial Disease.

Abstract excerpt

High attrition rates and loss of capital plague the drug discovery process. This is particularly evident for mitochondrial disease that typically involves neurological manifestations and is caused by nuclear or mitochondrial DNA defects. This group of heterogeneous disorders is difficult to target because of the variability of the symptoms among individual patients and the lack of viable modeling systems. The use...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Drug Discovery
• Share to High-Throughput Screening Assays